A Decade of Hardship, Finally Seeing the Light!
At 16:05 on December 28, 2021, the registration personnel of Asclepius Meditec received a short message from the National Medical Products Administration: "【NMPA Government Service】Dear Administrative Counterparty, on December 28, 2021, your paper approval document has been completed. The acceptance number is CQX2100189, and the product name is Hydrogen-Oxygen Nebulizer. Please collect it promptly at the Administrative Service Hall! If not collected in time, it will be mailed according to regulations. For any inquiries, please call 010-88331838. (Administrative Service Hall)"
(SMS Screenshot)
The registration change application for Asclepius Meditec's Hydrogen-Oxygen Nebulizer has been approved by the National Medical Products Administration, changing from the original "for use in medical institutions only" to "this product can be used in medical institutions and home care environments". This marks that after ten years of research and development, Asclepius Meditec's hydrogen-oxygen nebulizer has finally received national approval and officially entered the home care scenario!
(Screenshot of the official website of the National Medical Products Administration, notification of the approval of Asclepius Meditec's hydrogen-oxygen nebulizer change application)
National Medical Products Administration Approval Notification Website:
https://www.nmpa.gov.cn/zwfw/sdxx/sdxxylqx/qxpjfb/20211228160517175.html (Copy to check)
Hydrogen-Oxygen Nebulizer: Boon for Chronic Diseases
Under the careful guidance of Academician Zhong Nanshan, Asclepius Meditec, after ten years of research and development, has finally received national recognition and officially become a legitimate and compliant medical device: COPD patients can receive mixed hydrogen-oxygen mixed gas inhalation therapy in medical institutions or at home based on their clinical needs! China has also become the first country in the world to allow the use of hydrogen-oxygen inhalation therapy for COPD in all scenarios. This is not only a major breakthrough in global hydrogen-oxygen medicine but also a boon for patients with chronic diseases!
Legitimacy and Compliance of Hydrogen-Oxygen Inhalation
Patients inhaling hydrogen or hydrogen-oxygen mixtures is a medical act aimed at restoring health. Therefore, the state imposes strict controls on it. Only by using legitimate and compliant equipment can safety and effectiveness be guaranteed.
According to verified information on the official website of the National Medical Products Administration, the hydrogen-oxygen nebulizer developed by Asclepius Meditec is the first and only "hydrogen inhalation" and "hydrogen-oxygen inhalation" concept device in China to have obtained legitimate and compliant qualification approval. This is a great honor for Asclepius Meditec and a significant advancement in hydrogen-oxygen medicine! In the future, Asclepius Meditec will live up to the nation's expectations, continue to fight on the grand battlefield of humanity's battle against COPD, bring glory to China's medical innovation, and offer hope for the recovery of COPD patients in China!
As a latecomer in medical research and a populous country with 1.4 billion people, China's medical device regulatory approval process is far stricter than that of countries like Europe and the United States. From being approved as a "National Innovation" Class III medical device (for medical institution use only) in 2020 to being usable in all hospital and home scenarios in 2021, the Asclepius Hydrogen-Oxygen Nebulizer's tremendous leap forward is inseparable from the nation's high-level care and the meticulous guidance of superior leaders. As a member of China's medical innovation community, Asclepius Meditec is determined to fulfill its mission and strive tirelessly for the early realization of the grand goal of "freeing all sentient beings from the suffering of illness"!
Asclepius Meditec: Continuously Focusing on Human Challenges Such as Tumors and Neurological Diseases
With the strong support of over 50 Class A tertiary hospitals nationwide, Asclepius Meditec's hydrogen-oxygen nebulizer has participated in 9 multi-center clinical studies, 14 single-center clinical studies, and 7 National Natural Science Foundation projects. A total of 65 SCI papers have been published, covering research on a wide range of diseases. Including:
On this basis, we look forward to more medical colleagues joining the scientific research work of Asclepius Meditec's hydrogen-oxygen medicine, jointly promoting the continuous development of this medical innovation. Asclepius Meditec will also live up to the mission entrusted by the nation, continue to apply for more indications, propose more hydrogen-oxygen medical solutions for issues such as population aging and urban sub-health, and contribute more strength to the national grand health cause!
At this moment of national approval and celebration, we first express our gratitude for the nation's trust and the support of our superiors! We call on the broad medical community to pay attention to the development of hydrogen-oxygen medicine in China, and welcome those with aspirations to join the Asclepius Meditec camp, working together for the grand goal of human health!
